Action Pharma and Bachem Cooperate on AP214

Action Pharma A/S and Bachem have announced their cooperation on AP214, Action Pharma's lead compound, about to enter Phase 2 clinical trials in post-surgical organ failure. Since 2002, Bachem has supported Action Pharma by producing the peptide active ingredient of this drug candidate, by analytical method development, analytical method validation as well as by regulatory services. For the upcoming Phase 2 clinical trial, Bachem also supplies finished dosage forms under its Clinalfa brand.

The cooperation between Action Pharma and Bachem has been particularly close and also included involvement of Bachem in direct discussions with the US Food and Drug Administration, FDA, last year. Action Pharma has completed clinical Phase 1A, 1B and 1C studies and filed an Investigational New Drug Application with the FDA in November 2007. With AP405, Action Pharma has a second peptide-based development compound in its pipeline. This project, targeted at atopic dermatitis, is currently in pre-clinical development.

Also for AP405, Bachem is the partner for process development, production and related services.

For further information please contact:

Søren Nielsen,

CEO

Tel: +45 23 24 45 33

Email: sn@actionpharma.com

Or visit: www.actionpharma.com